The aim of the project is to construct magnetic nanoparticles carriers functionalized with Hsp70 and cmHsp70.1 monoclonal antibodies and to estimate their tumor-specificity and selectivity in in vitro experiments with tumor cells of several types including melanoma, glioblastoma and others. On the second stage using model of intracranial C6 glioblastoma in rats the dose of nanoparticles and time for the their retention will be determined with the aid of magnetic resonance imaging with the specific relation to tumor contrast enhancing parameters. The specificity of conjugates towards intracranial tumor will be compared with standard contrast agents. The data will form the ground for the preclinical and further clinical trials of the nanoparticles-based technology.